In the realm of thyroid cancer, where iodine treatment falls short for some, researchers explored a new ally. The thyroid-stimulating hormone receptor (TSHR) took the spotlight, showing up in 62% of patients’ thyroid tissues. With a specially crafted radiolabeled compound, researchers witnessed TSHR’s potential for imaging differentiated thyroid cancer. This breakthrough hints at a fresh diagnostic approach for cases resisting conventional treatments, shedding light on a promising avenue for improved patient care.
Journal Article by Gimblet GR, Whitt J (…) Jaskula-Sztul R et 15 al. in BMC Surg
Copyright © 2023 Elsevier Inc. All rights reserved.